Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Chronic urticaria: update on the pathogensis and emerging treatments (CROSBI ID 717882)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | domaća recenzija

Peternel, Sandra Chronic urticaria: update on the pathogensis and emerging treatments // 7. kongres hrvatskih dermatovenerologa s međunarodnim sudjelovanjem. 2022

Podaci o odgovornosti

Peternel, Sandra

engleski

Chronic urticaria: update on the pathogensis and emerging treatments

Chronic spontaneous urticaria (CSU) is characterized by typically short-lived wheals, angioedema or both, which occur spontaneously and last longer than 6 weeks. This term is used for the most common form of chronic urticaria (CU). The annual prevalence of CU is 0.5% to 2.3%, and its lifetime prevalence is 1.8% across several countries in the United States and Europe. Omalizumab is the only currently approved treatment for antihistamine-refractory CSU, and additional and better treatments for CSU and other subtypes of CU are needed. Objective of the presentation is to provide an update on the pathogenesis of CSU and to discuss novel therapeutic agents that are under development for the treatment of CU/CSU. This update will cover recent findings on the pathogenesis of CSU regarding its two endotypes: type I autoimmune (or autoallergic) CSU, triggered by IgE to autoallergens, and type IIb autoimmune CSU, which is due to mast cell-directed autoantibodies. Several reports suggest that type I autoimmune and type IIb autoimmune CSU patients differ in their disease features, laboratory markers, and response to omalizumab treatment. Newer therapeutical agents are emerging that may offer additional alternatives to antihistamines and omalizumab for CU/CSU patients, including anti-IgE agents, anti-cytokine and anti-receptor biologics, and BTK inhibitors, which will be reviewed.

chronic urticaria ; angioedema ; omalizumab ; autoimmunity ; Bruton tyrosine kinase

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

63T2SAAFPPG8N6SPZ

2022.

objavljeno

Podaci o matičnoj publikaciji

7. kongres hrvatskih dermatovenerologa s međunarodnim sudjelovanjem

Podaci o skupu

7. kongres hrvatskih dermatovenerologa s međunarodnim sudjelovanjem

pozvano predavanje

05.08.2022-08.08.2022

Vodice, Hrvatska

Povezanost rada

Kliničke medicinske znanosti, Temeljne medicinske znanosti